UNSPSC 51386101: Exisulind

This classification denotes a cyclooxygenase inhibitor with the molecular formula C20H17FO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K619IIG2R9, chemically known as 1h-indene-3-acetic acid, 5-fluoro-2-methy l-1-((4-(methylsulfonyl)phenyl)methylene)- but generally known as exisulind, which bears US NIH Compound Identifier 5472495. The term EXISULIND is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). Most nations schedule exisulind under HS 29309085 and SITC 51549.

As of Q4 2014, EXISULIND remains the US FDA Preferred Term for this commodity. Exisulind bears US NLM identifiers UMLS ID C0075616 and NCI Concept Code C1239. SMILES: CC\1=C(C2=C(/C1=C\C3=CC=C(C=C3)S(=O)(=O)C)C=CC(=C2)F)CC(=O)O.

UNSPSC 51386101 Exisulind, a Commodity code, maps poorly to actual state and local procurement activity in the recent record; the code appears to designate a specific pharmaceutical ingredient, but the opportunities tagged under it involve broad pharmaceutical procurement (naloxone, multi-source generics, and direct-to-manufacturer prescription models) that fall outside the scope of a single active pharmaceutical ingredient. State and local governments do procure medications and pharmaceutical products through competitive bidding and cooperative purchasing arrangements, but the recent opportunities shown do not align with exisulind specifically. Seminole County, Florida, Departments of Health and Human Services across state agencies (Texas HHS Commission, Minnesota Department of Administration), and county health departments are among the issuing bodies conducting pharmaceutical procurement through IFB, RFI, and RFP notice types. The work encompasses purchase and delivery of finished pharmaceutical products (naloxone kits, over-the-counter items, multi-source generics) destined for public health, correctional, or employee health benefit programs, with quarterly or regular delivery schedules and compliance requirements around cGMP, DSCSA, FDA registration, and E-Verify.

Geographic activity centers on Florida, Texas, and Minnesota with cooperative purchasing extending to other states (Oregon participates in MMCAP). Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products supplied through three authorized wholesalers with pricing evaluation weighted 75 percent on competitiveness. The code shows no direct recent activity clearly tied to exisulind as a single ingredient; procurement professionals evaluating this code should verify whether exisulind-specific demand exists at target jurisdictions or whether the code was incorrectly applied to these broader pharmaceutical opportunities.